Carglumic acid
Carglumic acid is an orphan drug used for the treatment of hyperammonaemia in patients with N-acetylglutamate synthase deficiency. This rare genetic disorder reslits in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and cause neurologic problems, cerebral edema, coma, and death. Carglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010.
Structure for HMDB15673 (Carglumic acid)
C6H10N2O5
190.154
190.05897144
(2S)-2-(carbamoylamino)pentanedioic acid
carglumic acid
1188-38-1
LCQLHJZYVOQKHU-VKHMYHEASA-N
This compound belongs to the class of chemical entities known as glutamic acid and derivatives. These are compounds containing glutamic acid or a derivative thereof resliting from reaction of glutamic acid at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
Chemical entities
Organic compounds
Organic acids and derivatives
Carboxylic acids and derivatives
Glutamic acid and derivatives
Aliphatic acyclic compounds
Expected but not Quantified
Not Available
Not Available
Solid
LC-MS/MS Spectrum – LC-ESI-QQ , negativesplash10-000j-0900000000-b40c000081e1b7470cc1View in MoNA
LC-MS/MS Spectrum – LC-ESI-QQ , negativesplash10-002b-0900000000-eb1fe6fcbdc6f376370eView in MoNA
LC-MS/MS Spectrum – LC-ESI-QQ , negativesplash10-0udi-0900000000-245f4056f629592bd99fView in MoNA
LC-MS/MS Spectrum – LC-ESI-QQ , negativesplash10-0udi-4900000000-3a5f21eb40fd1821e24fView in MoNA
LC-MS/MS Spectrum – LC-ESI-QQ , negativesplash10-0pb9-9500000000-67aafe80496b10392ef0View in MoNA
Predicted LC-MS/MS Spectrum – 10V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 20V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 40V, PositiveNot Available
Predicted LC-MS/MS Spectrum – 10V, NegativeNot Available
Predicted LC-MS/MS Spectrum – 20V, NegativeNot Available
Predicted LC-MS/MS Spectrum – 40V, NegativeNot Available
Not Available
Not Available
Not Available
Not Available
None
None
DB06775
Not Available
Not Available
Not Available
Not Available
Not Available
108351
C05829
Not Available
Not Available
Carglumic_acid
HMDB15673
HMDB15673
Not Available
121396
Not Available
775731
- Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C: N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol. 2002 Dec;52(6):845-9. [PubMed:12447942 ]
- Caldovic L, Morizono H, Daikhin Y, Nissim I, McCarter RJ, Yudkoff M, Tuchman M: Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. J Pediatr. 2004 Oct;145(4):552-4. [PubMed:15480384 ]
- Thompson CA: Carglumic acid approved to treat genetic hyperammonemia. Am J Health Syst Pharm. 2010 May 1;67(9):690. doi: 10.2146/news100031. [PubMed:20410539 ]
- Haberle J: Role of carglumic acid in the treatment of acute hyperammonemia due to N-acetylglutamate synthase deficiency. Ther Clin Risk Manag. 2011;7:327-32. doi: 10.2147/TCRM.S12703. Epub 2011 Aug 2. [PubMed:21941437 ]
- European Medicines Agency [Link]
Enzymes
- General function:
- Involved in catalytic activity
- Specific function:
- Involved in the urea cycle of ureotelic animals where the enzyme plays an important role in removing excess ammonia from the cell.
- Gene Name:
- CPS1
- Uniprot ID:
- P31327
- Molecular weight:
- 165649.075
References
- Authors unspecified: Carglumic acid: a second look. Confirmed progress in a rare urea cycle disorder. Prescrire Int. 2008 Apr;17(94):50-1. [PubMed:18516804 ]
- Hart EJ, Powers-Lee SG: Role of Cys-1327 and Cys-1337 in redox sensitivity and allosteric monitoring in human carbamoyl phosphate synthetase. J Biol Chem. 2009 Feb 27;284(9):5977-85. doi: 10.1074/jbc.M808702200. Epub 2008 Dec 23. [PubMed:19106093 ]
- Kasapkara CS, Ezgu FS, Okur I, Tumer L, Biberoglu G, Hasanoglu A: N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur J Pediatr. 2011 Jun;170(6):799-801. doi: 10.1007/s00431-010-1362-9. Epub 2011 Jan 5. [PubMed:21207059 ]